Immuno-Oncology Conference 2018

SMi Group26 - 27 September, London, UK.
Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies. SMi's Immuno-Oncology Conference will focus on a few key areas of the field with representation of the whole industry, under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress.

Agenda - Over 15 engaging presentations, case studies, keynote addresses, including:

  • Targeting immune checkpoints with Humabody VH therapeutics
  • Recent advances in providing durable disease control with Keytruda as an anti-cancer therapy
  • Tumour mutation burden and the potential of its use as an indication of treatment choice
  • Unwanted immunogenicity and functionality testing of immuno-oncology drugs
  • New techniques, such as the emerging applications of liquid biopsies, in Immuno-Oncology

Speakers - Over 15 leading experts in Immuno-Oncology field, including:

  • James Legg, Vice President R&D, Crescendo Biologics
  • Andrew Exley, Medical Assessor, MHRA
  • Harry Smith, Medical Scientist, Gilead Sciences
  • Grace Macaulay, Global Safety Physician Patient Safety Oncology, MedImmune
  • David Giljohan, CEO, Exicure
  • KandeepanGaneshalingam, Executive Director, Oncology Therapeutic Area Head, European Clinical Development, MSD
  • RochanaWickramasinghe, Director of Oncology Evaluation, AstraZeneca

Workshops - Carefully selected topics for further on-sight training. 2 pre-conference workshops (25 September) to provide in-depth knowledge on specific topics:

  • Strategic Competitive Intelligence in the Immuno-Oncology space - hosted by LucidQuest Ventures
  • Could the Microbiome boost Cancer Immuno-Therapy - hosted by ImmuneBiotech and Lund University

Networking - it is at the forefront of SMi events. 5+ hours of pure networking guaranteed. Follow event updates to be in the know about who will be joining the conversation.

For further details, please visit:
http://www.immuno-oncology-conference.com

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...